Telmisartan prevention of LPS-induced microglia activation involves M2 microglia polarization via CaMKKβ-dependent AMPK activation

Brain, Behavior, and Immunity

Volumn 50, Issue , 2015, Pages 298-313

  Xu, Yuan ^a   Xu, Yazhou ^a   Wang, Yurong ^a   Wang, Yunjie ^a   He, Ling ^a   Jiang, Zhenzhou ^a   Huang, Zhangjian ^a   Liao, Hong ^a   Li, Jia ^b   Saavedra, Juan M ^c   Zhang, Luyong ^a   Pang, Tao ^a,c  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

^b SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

^c GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

AMP activated protein kinase; Microglia polarization; Neuroinflammation; Telmisartan

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 2 RECEPTOR; CALMODULIN DEPENDENT PROTEIN KINASE KINASE BETA; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; LIPOPOLYSACCHARIDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROTEIN SERINE THREONINE KINASE; TELMISARTAN; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; BENZIMIDAZOLE DERIVATIVE; BENZOIC ACID DERIVATIVE; CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE KINASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ASTROCYTE; BODY WEIGHT; CELL ACTIVATION; CELL POLARITY; CONTROLLED STUDY; CYTOKINE RELEASE; FOOD INTAKE; GENE EXPRESSION; LOCOMOTION; MALE; MICROGLIA; MICROGLIA ACTIVATION; MICROGLIA POLARIZATION; MOUSE; NERVOUS SYSTEM INFLAMMATION; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; ANIMAL; BRAIN CORTEX; CHEMICALLY INDUCED; DRUG EFFECTS; ENCEPHALITIS; HELA CELL LINE; HUMAN; ILLNESS BEHAVIOR; METABOLISM; PHYSIOLOGY; SIGNAL TRANSDUCTION;

AMP-ACTIVATED PROTEIN KINASES; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; BENZIMIDAZOLES; BENZOATES; CALCIUM-CALMODULIN-DEPENDENT PROTEIN KINASE KINASE; CELL POLARITY; CEREBRAL CORTEX; ENCEPHALITIS; HELA CELLS; HUMANS; ILLNESS BEHAVIOR; LIPOPOLYSACCHARIDES; MICE; MICROGLIA; SIGNAL TRANSDUCTION;

EID: 84937485537     PISSN: 08891591     EISSN: 10902139     Source Type: Journal    
DOI: 10.1016/j.bbi.2015.07.015     Document Type: Article

References (58)

1. Amato S., Man H.Y. Bioenergy sensing in the brain: the role of AMP-activated protein kinase in neuronal metabolism, development and neurological diseases. Cell Cycle 2011, 10:3452-3460.
2. Bai A., Ma A.G., Yong M., Weiss C.R., Ma Y., Guan Q., Bernstein C.N., Peng Z. AMPK agonist downregulates innate and adaptive immune responses in TNBS-induced murine acute and relapsing colitis. Biochem. Pharmacol. 2010, 80:1708-1717.
3. Benicky J., Sanchez-Lemus E., Honda M., Pang T., Orecna M., Wang J., Leng Y., Chuang D.M., Saavedra J.M. Angiotensin II AT1 receptor blockade ameliorates brain inflammation. Neuropsychopharmacology 2011, 36:857-870.
4. Block M.L., Zecca L., Hong J.S. Microglia-mediated neurotoxicity: uncovering the molecular mechanisms. Nat. Rev. Neurosci. 2007, 8:57-69.
5. Buler M., Astsinki S.M., Skoumal R., Komka Z., Tóth M., Kerkelä R., Georgiadi A., Kersten S., Hakkola J. Energy-sensing factors coactivator peroxisome proliferator-activated receptor γ coactivator 1-α (PGC-1α) and AMP-activated protein kinase control expression of inflammatory mediators in liver: induction of interleukin 1 receptor antagonist. J. Biol. Chem. 2012, 287:1847-1860.
6. Chhor V., Le Charpentier T., Lebon S., Ore M.V., Celador I.L., Josserand J., Degos V., Jacotot E., Hagberg H., Savman K., Mallard C., Gressens P., Fleiss B. Characterization of phenotype markers and neuronotoxic potential of polarised primary microglia in vitro. Brain. Behav. Immun. 2013, 32:70-85.
7. Clark S.M., Michael K.C., Klaus J., Mert A., Romano-Verthelyi A., Sand J., Tonelli L.H. Dissociation between sickness behavior and emotionality during lipopolysaccharide challenge in lymphocyte deficient Rag2 mice. Behav. Brain. Res. 2014, 278:74-82.
8. David S., Kroner A. Repertoire of microglial and macrophage responses after spinal cord injury. Nat. Rev. Neurosci. 2011, 12:388-399.
9. Erbe D.V., Gartrell K., Zhang Y.L., Suri V., Kirincich S.J., Will S., Perreault M., Wang S., Tobin J.F. Molecular activation of PPARgamma by angiotensin II type 1-receptor antagonists. Vascul. Pharmacol. 2006, 45:154-162.
10. Garrido-Gil P., Joglar B., Rodriguez-Perez A.I., Guerra M.J., Labandeira-Garcia J.L. Involvement of PPAR-gamma in the neuroprotective and anti-inflammatory effects of angiotensin type 1 receptor inhibition: effects of the receptor antagonist telmisartan and receptor deletion in a mouse MPTP model of Parkinson's disease. J. Neuroinflammation 2012, 9:38.
11. Giri S., Nath N., Smith B., Viollet B., Singh A.K., Singh I. 5-Aminoimidazole-4-carboxamide-1-beta-4-ribofuranoside inhibits proinflammatory response in glial cells: a possible role of AMP-activated protein kinase. J. Neurosci. 2004, 24:479-487.
12. Godbout J.P., Chen J., Abraham J., Richwine A.F., Berg B.M., Kelley K.W., Johnson R.W. Exaggerated neuroinflammation and sickness behavior in aged mice following activation of the peripheral innate immune system. FASEB J. 2005, 19:1329-1331.
13. Green M.F., Anderson K.A., Means A.R. Characterization of the CaMKKbeta-AMPK signaling complex. Cell. Signal. 2011, 23:2005-2012.
14. Haroon E., Raison C.L., Miller A.H. Psychoneuroimmunology meets neuropsychopharmacology: translational implications of the impact of inflammation on behavior. Neuropsychopharmacology 2012, 37:137-162.
15. Heijnen C.J., Kavelaars A. Neuro-immune, behavioral and molecular aspects of brain damage. Brain Behav. Immun. 2010, 24:705-707.
16. Henn A., Lund S., Hedtjarn M., Schrattenholz A., Porzgen P., Leist M. The suitability of BV2 cells as alternative model system for primary microglia cultures or for animal experiments examining brain inflammation. ALTEX 2009, 26:83-94.
17. Henry C.J., Huang Y., Wynne A., Hanke M., Himler J., Bailey M.T., Sheridan J.F., Godbout J.P. Minocycline attenuates lipopolysaccharide (LPS)-induced neuroinflammation, sickness behavior, and anhedonia. J. Neuroinflammation 2008, 5:15.
18. Hu X., Leak R.K., Shi Y., Suenaga J., Gao Y., Zheng P., Chen J. Microglial and macrophage polarization - new prospects for brain repair. Nat. Rev. Neurol. 2015, 11:56-64.
19. Hu X., Li P., Guo Y., Wang H., Leak R.K., Chen S., Gao Y., Chen J. Microglia/macrophage polarization dynamics reveal novel mechanism of injury expansion after focal cerebral ischemia. Stroke 2012, 43:3063-3070.
20. Jiang T., Yu J.T., Zhu X.C., Wang H.F., Tan M.S., Cao L., Zhang Q.Q., Gao L., Shi J.Q., Zhang Y.D., Tan L. Acute metformin preconditioning confers neuroprotection against focal cerebral ischaemia by pre-activation of AMPK-dependent autophagy. Br. J. Pharmacol. 2014, 171:3146-3157.
21. Jimenez S., Baglietto-Vargas D., Caballero C., Moreno-Gonzalez I., Torres M., Sanchez-Varo R., Ruano D., Vizuete M., Gutierrez A., Vitorica J. Inflammatory response in the hippocampus of PS1M146L/APP751SL mouse model of Alzheimer's disease: age-dependent switch in the microglial phenotype from alternative to classic. J. Neurosci. 2008, 28:11650-11661.
22. Konsman J.P., Dantzer R. How the immune and nervous systems interact during disease-associated anorexia. Nutrition 2001, 17:664-668.
23. Leff T. AMP-activated protein kinase regulates gene expression by direct phosphorylation of nuclear proteins. Biochem. Soc. Trans. 2003, 31:224-227.
24. Li, B.H., Liao, S.Q., Yin, Y.W., Long, C.Y., Guo, L., Cao, X.J., Liu, Y., Zhou, Y., Gao, C.Y., Zhang, L.L., Li, J.C., in press. Telmisartan-induced PPARgamma activity attenuates lipid accumulation in VSMCs via induction of autophagy. Mol. Biol. Rep. doi:10.1007/s11033-014-3757-6.
25. Li J., McCullough L.D. Effects of AMP-activated protein kinase in cerebral ischemia. J. Cereb. Blood Flow Metab. 2010, 30:480-492.
26. Liao B., Zhao W., Beers D.R., Henkel J.S., Appel S.H. Transformation from a neuroprotective to a neurotoxic microglial phenotype in a mouse model of ALS. Exp. Neurol. 2012, 237:147-152.
27. Lizcano J.M., Goransson O., Toth R., Deak M., Morrice N.A., Boudeau J., Hawley S.A., Udd L., Makela T.P., Hardie D.G., Alessi D.R. LKB1 is a master kinase that activates 13 kinases of the AMPK subfamily, including MARK/PAR-1. EMBO J. 2004, 23:833-843.
28. Lu D.Y., Tang C.H., Chen Y.H., Wei I.H. Berberine suppresses neuroinflammatory responses through AMP-activated protein kinase activation in BV-2 microglia. J. Cell. Biochem. 2010, 110:697-705.
29. Manna P., Jain S.K. l-cysteine and hydrogen sulfide increase PIP3 and AMPK/PPARγ expression and decrease ROS and vascular inflammation markers in high glucose treated human U937 monocytes. J. Cell. Biochem. 2013, 114:2334-2345.
30. Mantovani A., Biswas S.K., Galdiero M.R., Sica A., Locati M. Macrophage plasticity and polarization in tissue repair and remodelling. J. Pathol. 2013, 229:176-185.
31. Mittelbronn M. The M1/M2 immune polarization concept in microglia: a fair transfer?. Neuroimmunol. Neuroinflammation 2014, 1:6-7.
32. Mogi M., Li J.M., Iwanami J., Min L.J., Tsukuda K., Iwai M., Horiuchi M. Angiotensin II type-2 receptor stimulation prevents neural damage by transcriptional activation of methyl methanesulfonate sensitive 2. Hypertension 2006, 48:141-148.
33. Moreno M., Lombardi A., Silvestri E., Senese R., Cioffi F., Goglia F., Lanni A., de Lange P. PPARs: Nuclear receptors controlled by, and controlling, nutrient handling through nuclear and cytosolic signaling. PPAR Res. 2010, pii: 435689. 10.1155/2010/435689.
34. Morrison A., Li J. PPAR-γ and AMPK-advantageous targets for myocardial ischemia/reperfusion therapy. Biochem. Pharmacol. 2011, 82:195-200.
35. Mounier R., Theret M., Arnold L., Cuvellier S., Bultot L., Goransson O., Sanz N., Ferry A., Sakamoto K., Foretz M., Viollet B., Chazaud B. AMPKalpha1 regulates macrophage skewing at the time of resolution of inflammation during skeletal muscle regeneration. Cell Metab. 2013, 18:251-264.
36. Nath N., Khan M., Paintlia M.K., Singh I., Hoda M.N., Giri S. Metformin attenuated the autoimmune disease of the central nervous system in animal models of multiple sclerosis. J. Immunol. 2009, 182:8005-8014.
37. Nimmerjahn A., Kirchhoff F., Helmchen F. Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo. Science 2005, 308:1314-1318.
38. O'Neill L.A., Hardie D.G. Metabolism of inflammation limited by AMPK and pseudo-starvation. Nature 2013, 493:346-355.
39. Odegaard J.I., Ricardo-Gonzalez R.R., Goforth M.H., Morel C.R., Subramanian V., Mukundan L., Red Eagle A., Vats D., Brombacher F., Ferrante A.W., Chawla A. Macrophage-specific PPARgamma controls alternative activation and improves insulin resistance. Nature 2007, 447:1116-1120.
40. Palomer X., Salvadó L., Barroso E., Vázquez-Carrera M. An overview of the crosstalk between inflammatory processes and metabolic dysregulation during diabetic cardiomyopathy. Int. J. Cardiol. 2013, 168:3160-3172.
41. Pang T., Benicky J., Wang J., Orecna M., Sanchez-Lemus E., Saavedra J.M. Telmisartan ameliorates lipopolysaccharide-induced innate immune response through peroxisome proliferator-activated receptor-gamma activation in human monocytes. J. Hypertens. 2012, 30:87-96.
42. Pang T., Wang J., Benicky J., Sanchez-Lemus E., Saavedra J.M. Telmisartan directly ameliorates the neuronal inflammatory response to IL-1beta partly through the JNK/c-Jun and NADPH oxidase pathways. J. Neuroinflammation 2012, 9:102.
43. Perry V.H., Nicoll J.A., Holmes C. Microglia in neurodegenerative disease. Nat. Rev. Neurol. 2010, 6:193-201.
44. Racioppi L., Means A.R. Calcium/calmodulin-dependent protein kinase kinase 2: roles in signaling and pathophysiology. J. Biol. Chem. 2012, 287:31658-31665.
45. Racioppi L., Noeldner P.K., Lin F., Arvai S., Means A.R. Calcium/calmodulin-dependent protein kinase kinase 2 regulates macrophage-mediated inflammatory responses. J. Biol. Chem. 2012, 287:11579-11591.
46. Ransohoff R.M., Perry V.H. Microglial physiology: unique stimuli, specialized responses. Annu. Rev. Immunol. 2009, 27:119-145.
47. Saavedra J.M. Angiotensin II AT(1) receptor blockers as treatments for inflammatory brain disorders. Clin. Sci. (Lond) 2012, 123:567-590.
48. Sag D., Carling D., Stout R.D., Suttles J. Adenosine 5'-monophosphate-activated protein kinase promotes macrophage polarization to an anti-inflammatory functional phenotype. J. Immunol. 2008, 181:8633-8641.
49. Saijo K., Glass C.K. Microglial cell origin and phenotypes in health and disease. Nat. Rev. Immunol. 2011, 11:775-787.
50. Shiota A., Shimabukuro M., Fukuda D., Soeki T., Sato H., Uematsu E., Hirata Y., Kurobe H., Maeda N., Sakaue H., Masuzaki H., Shimomura I., Sata M. Telmisartan ameliorates insulin sensitivity by activating the AMPK/SIRT1 pathway in skeletal muscle of obese db/db mice. Cardiovasc. Diabetol. 2012, 11:139.
51. Shiota A., Shimabukuro M., Fukuda D., Soeki T., Sato H., Uematsu E., Hirata Y., Kurobe H., Sakaue H., Nakaya Y., Masuzaki H., Sata M. Activation of AMPK-Sirt1 pathway by telmisartan in white adipose tissue: A possible link to anti-metabolic effects. Eur. J. Pharmacol. 2012, 692:84-90.
52. Tsukuda K., Mogi M., Iwanami J., Min L.J., Sakata A., Jing F., Iwai M., Horiuchi M. Cognitive deficit in amyloid-beta-injected mice was improved by pretreatment with a low dose of telmisartan partly because of peroxisome proliferator-activated receptor-gamma activation. Hypertension 2009, 54:782-787.
53. Villapol S., Yaszemski A.K., Logan T.T., Sanchez-Lemus E., Saavedra J.M., Symes A.J. Candesartan, an angiotensin II AT(1)-receptor blocker and PPAR-gamma agonist, reduces lesion volume and improves motor and memory function after traumatic brain injury in mice. Neuropsychopharmacology 2012, 37:2817-2829.
54. Wang J., Pang T., Hafko R., Benicky J., Sanchez-Lemus E., Saavedra J.M. Telmisartan ameliorates glutamate-induced neurotoxicity: roles of AT(1) receptor blockade and PPARgamma activation. Neuropharmacology 2014, 79:249-261.
55. Wang R., Li J.J., Diao S., Kwak Y.D., Liu L., Zhi L., Büeler H., Bhat N.R., Williams R.W., Park E.A., Liao F.F. Metabolic stress modulates Alzheimer's β-secretase gene transcription via SIRT1-PPARγ-PGC-1 in neurons. Cell Metab. 2013, 17:685-694.
56. Zhao J., Yue W., Zhu M.J., Sreejayan N., Du M. AMP-activated protein kinase (AMPK) cross-talks with canonical Wnt signaling via phosphorylation of beta-catenin at Ser 552. Biochem. Biophys. Res. Commun. 2010, 395:146-151.
57. Zhou X., Cao Y., Ao G., Hu L., Liu H., Wu J., Wang X., Jin M., Zheng S., Zhen X., Alkayed N.J., Jia J., Cheng J. CaMKKbeta-dependent activation of AMP-activated protein kinase is critical to suppressive effects of hydrogen sulfide on neuroinflammation. Antioxid. Redox Signal. 2014, 21:1741-1758.
58. Zorad S., Dou J.T., Benicky J., Hutanu D., Tybitanclova K., Zhou J., Saavedra J.M. Long-term angiotensin II AT1 receptor inhibition produces adipose tissue hypotrophy accompanied by increased expression of adiponectin and PPARgamma. Eur. J. Pharmacol. 2006, 552:112-122.